

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Tolebrutinib for treating secondary progressive multiple sclerosis ID6351

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Sanofi (tolebrutinib)	All Wales Therapeutics and Toxicology
(3333.0.1)	Centre
Patient/carer groups	Allied Health Professionals Federation
Brain and Spine Foundation	Board of Community Health Councils in
Brain Charity	Wales
MS-UK	British National Formulary
Multiple Sclerosis National Therapy	Care Quality Commission
Centres	Department of Health, Social Services
Multiple Sclerosis Society	and Public Safety for Northern Ireland
Multiple Sclerosis Trust	Healthcare Improvement Scotland
Neuro Therapy Network	Health Technology Wales
Neurological Alliance	Medicines and Healthcare products
Shift.ms	Regulatory Agency
 South Asian Health Foundation 	Multiple Sclerosis Society Wales
Specialised Healthcare Alliance	National Association of Primary Care
·	National Pharmacy Association
Healthcare professional groups	Neurological Alliance of Scotland
 Association of British Neurologists 	NHS Confederation
 British Association of Neuroscience 	NHS Wales Joint Commissioning
Nurses	Committee
 British Geriatrics Society 	Scottish Medicines Consortium
 British Neuropathological Society 	Wales Neurological Alliance
 British Society for Blood and Marrow 	Welsh Government
Transplantation	
 British Society of Rehabilitation 	Possible comparator companies
Medicine	• N/A
 Chartered Society of Physiotherapy 	
 Institute of Neurology 	Relevant research groups
 London MS-AHSCT Collaborative 	Brain Research UK
Group	Cochrane Multiple Sclerosis and Rare
 National Neurosciences Advisory 	Diseases of the Central Nervous
Group	System Group
Primary Care and Community	Genomics England
Neurology Society	MRC Clinical Trials Unit
Royal College of General Practitioners	National Institute for Health Research
Royal College of Nursing	

Provisional stakeholder list for the evaluation of tolebrutinib for treating secondary progressive multiple sclerosis ID6351



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Occupational Therapists Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Therapists in MS UK Clinical Pharmacy Association UK Multiple Sclerosis Specialist Nurse Association Others	 Associated Public Health groups Public Health Wales UK Health Security Agency
 Department of Health and Social Care NHS England 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).





Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.